HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases - Wikidata - awgldk - TriplyDB

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

http://www.wikidata.org/entity/Q24634978

about

Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium Multi-peptide nLC-PC-IDMS-SRM-based assay for the quantification of biomarkers in the chicken ovarian cancer model Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients Human epididymis protein 4 reference limits and natural variation in a Nordic reference population Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers HE4, CA-125, and cystic ovarian mass Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.Early detection biomarkers for ovarian cancer.Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer.Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.HE4 (WFDC2) gene overexpression promotes ovarian tumor growth HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.HE4-test of urine and body fluids for diagnosis of gynecologic cancer.Detection of Human Epididymis Protein 4 (HE4) in Human Serum Samples Using a Specific Monoclonal Antibody-Based Sandwich Enzyme-Linked Immunosorbent Assay (ELISA).The role of biomarkers in the management of epithelial ovarian cancer.RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Red Snappers and Red Herrings: Pelvic Tuberculosis Causing Elevated CA 125 and Mimicking Advanced Ovarian Cancer. A Case Report and Literature Review.Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression.Is serum human epididymis protein 4 ready for prime time?HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

P2860

Q26768480-FB22C692-06B8-4109-81AD-48A6AB3ED023 Q26992102-446375CA-9E28-44C6-810E-6FB23E49E128 Q30414041-23D06FDB-B732-428C-9BF3-25A2E122B4A4 Q32173966-9EFE199B-108C-4BF6-9731-5DE279C3FE45 Q33624809-176848BD-790F-43E7-BD3C-E6568999CC56 Q34180244-9C532154-F7D1-448D-9B94-306856E38D05 Q34306120-DB5947CC-4D2C-4484-A5BE-05ADBFA8C181 Q34372843-270A4CFD-A500-47AF-91E9-F35ECDAAA43E Q34391119-9ECC3F3C-CB7F-4AC7-A657-53741E3A7B50 Q35589339-C7AAF367-B0A1-4EFD-8397-3229D19B43F0 Q35605987-CCEEF799-586A-4B73-8ADD-1D5580647BA5 Q35677625-F004AF24-F967-49B6-9335-45F0A1D02365 Q35886081-290EDC12-81BF-4D41-AF4D-EE96922D6629 Q36076953-C1CD6961-AFD7-44A3-A6C1-8896B6CFD776 Q36346403-93757C94-7C0C-4171-AF2D-9311A2519AE7 Q36372283-87B437E8-F07C-4260-BF91-37E630D5489C Q36400522-D07825EA-C6E7-4BE1-A9C3-1D80F58E89D5 Q36520143-305276C4-69D7-450B-8742-161D10898C9C Q36752512-0C994A7F-6B5D-46A8-9D8D-15F2D45E4AA6 Q36996525-DAC1C1CC-539E-4109-A790-9E6FC998A107 Q37001660-22DD3905-8703-408D-AC86-462660F0E10B Q37111350-50161389-919E-4D35-AA9A-3B488A5DD2E5 Q37188163-B965DDE2-C0B6-4892-BF7B-14A700557699 Q37291762-33B12A98-DFE3-4FD3-BA71-1FB90FB42D2D Q37302215-D175326F-C364-43EF-ABC3-96DA88713751 Q37406838-E6D02AD4-B481-4E6A-99CB-CA6D98E23CE9 Q37434141-1B73B405-71DA-475B-8A45-F3699B32BE68 Q37611329-3A53F60B-FF03-4F27-8833-34E4092740CA Q38052927-63207850-8FE8-4536-A7AB-FE566D36B7EB Q38388103-871D779F-FB0C-42AC-80C0-F1BEDB742D24 Q38653169-DBB11F38-B1C8-4B19-AE34-545971ED6D35 Q38766453-63B9B364-5973-4F6B-B299-B6D98A0D7882 Q38811840-10796E0E-0E70-475F-BEAB-C305AA9F1F09 Q39281140-9CDD97DE-C2A9-4DA3-83BA-6CB38646F556 Q40056725-7BE333BE-C11D-403E-89B9-5DC4C73833B6 Q41173805-11030D46-1C6E-44CD-B14D-0C9FFC5E0DB8 Q41339319-606F50E9-51CF-4873-96ED-627D42AA98E5 Q44234643-30C6A0E6-2827-4E03-A4E8-C70A3D02C950 Q50773867-FD7B2D26-AE3B-44A9-8208-F8717DC2E81A Q51091632-A0585462-0B64-4814-B3CB-A882C923F23C

P2860

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

http://www.wikidata.org/entity/Q24634978

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HE4 a novel tumour marker for ...... s with gynaecological diseases

@ast

HE4 a novel tumour marker for ...... s with gynaecological diseases

@en

HE4 a novel tumour marker for ...... s with gynaecological diseases

@nl

type

label

HE4 a novel tumour marker for ...... s with gynaecological diseases

@ast

HE4 a novel tumour marker for ...... s with gynaecological diseases

@en

HE4 a novel tumour marker for ...... s with gynaecological diseases

@nl

prefLabel

HE4 a novel tumour marker for ...... s with gynaecological diseases

@ast

HE4 a novel tumour marker for ...... s with gynaecological diseases

@en

HE4 a novel tumour marker for ...... s with gynaecological diseases

@nl

P1433

Q24634978-D9797F1A-B9CD-4891-8CAF-3DD49F267842

P1476

Q24634978-622092B1-D849-4CD3-A272-4F4CC3E68A37

P2093

Q24634978-7751B974-8229-4FD4-B732-562E2179E3AD

Q24634978-7EDA15DB-BE01-4A30-AA4D-E0A85A79DFEC

Q24634978-A820FAB5-5D3D-46A3-8D9E-F5ADB915134D

Q24634978-A96DC103-CEBA-4AB8-A91A-439B13B25994

Q24634978-B1CA1A2D-6527-4022-83A6-78939B2ED1E4

Q24634978-E2DEA078-E0DC-4D71-89CF-DB1373EB1DE2

Q24634978-E5289D3F-E73B-4449-BD07-3491D40C51C2

Q24634978-E5756AAF-FE63-4B7B-92AA-753151B67015

P2860

Q24634978-01DCCC9F-37C9-4463-8FCC-0AAFA49261A6

Q24634978-0317ECDF-B84F-4A67-A4CF-A3FB0384C551

Q24634978-07771A44-7A35-4A1D-9975-8278654C025D

Q24634978-1F9FC290-B8E8-49B4-9344-777B3BCC6056

Q24634978-24D110BE-82A9-46E8-AA60-B178AEDCEF4D

Q24634978-2CCED9CA-B6E3-4239-8D07-735EE64E0852

Q24634978-2D5C9771-4066-43C1-B157-4D9EC75DC3BB

Q24634978-2DBE8B2E-EAB3-49A3-BB5E-AF8C6EF62F27

Q24634978-2FB1F070-601D-43A5-A1E2-BAA0BC7AE493

Q24634978-36DB41D0-C332-4845-9706-6B3ECEE50D80

P2888

Q24634978-BA95C39F-A9E9-4F73-BD1B-2C7D7AC7D947

P304

Q24634978-AAE74ACF-34A7-4AD4-8DEE-9FE72B36D7E2

P31

Q24634978-1A503BF5-1718-491E-A49D-34D09E5A5C19

P3181

Q24634978-6DB7C6FF-2D32-4EDC-87BD-3B4CDA70D7BB

P356

Q24634978-3CE39451-8EB2-49D4-9C6A-2EFCF0E377F8

P407

Q24634978-E8B07826-0F1F-4A0D-807E-61C8B2A6D8FF

P433

Q24634978-60F528C2-B161-4ED4-9C02-7AD682D389F9

P478

Q24634978-AAB90F26-75CF-481E-87C4-CE4B7228EAD9

P577

Q24634978-AF066EE9-DDA4-47AF-BA3C-9CAFA193ECCF

P5875

Q24634978-AC490103-B18D-488B-8852-7A75B3852F62

P6179

Q24634978-E28456F9-A05E-4A4C-9607-C3BCB23EDE5C

P698

Q24634978-AF12ECE4-9E82-4A79-953F-0FFA40BD08BF

P921

Q24634978-0A7AB94C-188B-4AD8-953A-C82B8217CA8C

Q24634978-EEF09C0C-65BF-4E68-95C8-9677C26E4800

P932

Q24634978-BC9E7BF7-E625-4B5A-8F73-85435AB21BA4

P3181

P356

S13277-011-0204-3

P1433

P1476

HE4 a novel tumour marker for ...... s with gynaecological diseases

@en

P2093

Aureli Torné

http://www.w3.org/2001/XMLSchema#string

Jaume Pahisa

http://www.w3.org/2001/XMLSchema#string

Jose Lejarcegui

http://www.w3.org/2001/XMLSchema#string

Jose M Augé

http://www.w3.org/2001/XMLSchema#string

Jose M Escudero

http://www.w3.org/2001/XMLSchema#string

Laura Foj

http://www.w3.org/2001/XMLSchema#string

Rafael Molina

http://www.w3.org/2001/XMLSchema#string

Xavier Filella

http://www.w3.org/2001/XMLSchema#string

P2860

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other

Comparison of Eight Computer Programs for Receiver-Operating Characteristic Analysis

Cancer statistics, 2007

Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Progress and challenges in screening for early detection of ovarian cancer.

Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

P2888

s13277-011-0204-3

P304

1087-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

42214

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S13277-011-0204-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51591860

http://www.w3.org/2001/XMLSchema#string

P6179

1020748748

http://www.w3.org/2001/XMLSchema#string

P698

21863264

http://www.w3.org/2001/XMLSchema#string

P921

P932

3195682

http://www.w3.org/2001/XMLSchema#string